Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Sarah L Kerns*, Ashley Amidon Morlang, Sharon M Lee, Derick R Peterson, Brian Marples, Hong Zhang, Kevin Bylund, Doug Rosenzweig, William Hall, Kim De Ruyck, Barry S Rosenstein, Richard G Stock, Antonio Gómez-Caamaño, Ana Vega, Paloma Sosa-Fajardo, Begoña Taboada-Valladares, Miguel E Aguado-Barrera, Chris Parker, Liv Veldeman, Valérie FonteyneRenée Bultijnck, Christopher J Talbot, R Paul Symonds, Kerstie Johnson, Tim Rattay, Adam Webb, Maarten Lambrecht, Dirk de Ruysscher, Ben Vanneste, Ananya Choudhury, Rebecca M Elliott, Elena Sperk, Carsten Herskind, Marlon R Veldwijk, Tiziana Rancati, Barbara Avuzzi, Riccardo Valdagni, David Azria, Marie-Pierre Farcy Jacquet, Jenny Chang-Claude, Petra Seibold, Catharine West, Michelle Janelsins, Yuhchyau Chen, Edward Messing, Gary Morrow, REQUITE consortium
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer'. Together they form a unique fingerprint.